Dr. José Placer

Dr. José Placer
Página Web informativa sobre HoLEP
Menú
Menú
Dr. José Placer
Página Web informativa sobre HoLEP
Menú
Menú

Dr. José Placer

Dr. Jose Placer

Formación académica

  • Licenciado en Medicina y Cirugía por la Universidad de Cantabria (1997)
  • Especialista en Urología (2004)
  • Doctor en Cirugía por la Universitat Autònoma de Barcelona (2005)
  • Profesor Asociado de Urología de la Universitat Autònoma de Barcelona (2006-2010)

Actividad profesional

  • Médico interno residente en Urología en el Hospital del Mar - Hospital de l’Esperança de Barcelona (1999-2004)
  • Médico adjunto especialista en Urología del Hospital del Mar - Hospital de l’Esperança de Barcelona (2004-2008)
  • Médico adjunto especialista en Urología del Hospital Universitari Vall d’Hebron de Barcelona (desde 2008)
  • Médico asociado especialista en Urología del Hospital Quirón - Dexeus de Barcelona (desde 2008)

Principales áreas de interés

  • Hiperplasia benigna de próstata
  • Cirugía del adenoma prostático
  • Cirugía prostática con láser
  • Trasplante renal

Pertenencia a asociaciones profesionales

  • Asociación Española de Urología (desde 2001)
  • European Association of Urology (desde 2007)
  • Colegiado en el Col.legi Oficial de Metges de Barcelona (nº 33924) desde 1999

Últimas publicaciones científicas

  1. Celma A, López R, Roche S, Planas J, Regis L, Placer J, Borque A, Esteban LM, de Torres I, Morote J. Are targeted prostate biopsies ready to replace systematic prostate biopsies? Actas Urol Esp (Engl Ed). 2019 Dec;43(10):573-578. English, Spanish. doi: 10.1016/j.acuro.2018.06.011. Epub 2019 Oct 31. PMID: 31679807.
  2. Schwartzmann I, Celma A, Gallardo I, Moreno O, Regis L, Placer J, Planas J, Trilla Herrero E, Morote Robles J. In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. Actas Urol Esp (Engl Ed). 2019 Sep;43(7):337-347. English, Spanish. doi: 10.1016/j.acuro.2019.01.010. Epub 2019 May 17. PMID: 31109736.
  3. Lorente D, Trilla E, Meseguer A, Arevalo J, Nemours S, Planas J, Placer J, Celma A, Salvador C, Regis L, Schwartzmann I, Morote J. The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. Actas Urol Esp (Engl Ed). 2019 Apr;43(3):118-123. English, Spanish. doi: 10.1016/j.acuro.2018.08.003. Epub 2018 Nov 19. PMID: 30466966.
  4. Regis L, Salazar A, Cuadras M, Miret E, Roche S, Celma A, Planas J, Lorente D, Placer J, Trilla E, Morote J. Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy. Actas Urol Esp (Engl Ed). 2019 Apr;43(3):137-142. English, Spanish. doi: 10.1016/j.acuro.2018.07.003. Epub 2018 Nov 9. PMID: 30420112.
  5.  Regis L, Celma A, Planas J, Lopez R, Roche S, Lorente D, Placer J, Trilla E, Morote J. The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1? Scand J Urol. 2019 Feb;53(1):21-25. doi: 10.1080/21681805.2018.1551243. Epub 2019 Jan 10. PMID: 30628520.
  6. Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, Ferrer R, Carles J, Regis L. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer. 2018 Apr;16(2):e491-e496. doi: 10.1016/j.clgc.2017.10.025. Epub 2017 Dec 2. PMID: 29198640.
  7. Trilla E, Konstantinidis C, Serres X, Lorente D, Planas J, Placer J, Salvador C, Celma A, Montealegre C, Morote J. Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses. Actas Urol Esp. 2017 Oct;41(8):497-503. English, Spanish. doi: 10.1016/j.acuro.2017.03.001. Epub 2017 Apr 28. PMID: 28457496.
  8. Lorente D, Trilla E, Meseguer A, Planas J, Placer J, Celma A, Salvador C, Regis L, Morote J. Systematic review of renal carcinoma prognostic factors. Actas Urol Esp. 2017 May;41(4):215-225. English, Spanish. doi:
    10.1016/j.acuro.2016.08.003. Epub 2016 Sep 20. PMID: 27659130.
  9. Planas J, Celma A, Placer J, Cuadras M, Regis L, Gasanz C, Trilla E, Salvador C, Lorente D, Morote J. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. Scand J Urol. 2016 Dec;50(6):425-428. doi: 10.1080/21681805.2016.1227876. Epub 2016 Sep 14. PMID: 27628623.
  10. Servian P, Celma A, Planas J, Placer J, de Torres IM, Morote J. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. Prostate. 2016 Dec;76(16):1501-1506. doi: 10.1002/pros.23234. Epub 2016 Jul 12. PMID: 27404228.
  11. Planas J, Celma A, Placer J, Maldonado X, Trilla E, Salvador C, Lorente D, Regis L, Cuadras M, Carles J, Morote J. Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy. Actas Urol Esp. 2016 Nov;40(9):549-555. English, Spanish. doi: 10.1016/j.acuro.2016.02.010. Epub 2016 May 17. PMID: 27207596.
  12. Morote J, Celma A, Planas J, Placer J, Ferrer R, de Torres I, Pacciuci R, Olivan M. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. Actas Urol Esp. 2016 JulAug;40(6):378-85. English, Spanish. doi: 10.1016/j.acuro.2016.01.004. Epub 2016 Feb 26. PMID: 26923032.
  13. Ferrándiz-Pulido C, Hernández-Losa J, Masferrer E, Vivancos A, Somoza R, Marés R, Valverde C, Salvador C, Placer J, Morote J, Pujol RM, Ramon y Cajal S, de Torres I, Toll A, García-Patos V. Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes Cancer. 2015 Oct;54(10):629-37. doi: 10.1002/gcc.22274. Epub 2015 Jul 27. PMID: 26216163.
  14. Servian P, Celma A, Planas J, Placer J, de Torres IM, Olivan M, Morote J. Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. Prostate. 2015 Oct;75(14):1669-75. doi: 10.1002/pros.23047. Epub 2015 Jul 17. PMID: 26184870.
  15. Sequeiros T, Bastarós JM, Sánchez M, Rigau M, Montes M, Placer J, Planas J, de Torres I, Reventós J, Pegtel DM, Doll A, Morote J, Olivan M. Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Prostate. 2015 Jul 1;75(10):1102-13. doi: 10.1002/pros.22995. Epub 2015 Apr 1. PMID: 25845829.
  16. Placer J, Planas J, Celma A, Morote J. Papel actual del antígeno prostático específico (PSA) y sus derivados en el diagnóstico del cáncer de próstata [Current role of protatic specific antigen (PSA) and its by-products in the diagnosis of prostate cancer]. Arch Esp Urol. 2015 Apr;68(3):210-28. Spanish. PMID: 25948795.
  17. Placer J, Salvador C, Planas J, Trilla E, Lorente D, Celma A, López MÁ, Morote J. Effects of holmium laser enucleation of the prostate on sexual function. J Endourol. 2015 Mar;29(3):332-9. doi: 10.1089/end.2014.0502. Epub 2014 Oct 21. PMID: 25133981.
  18. Olivan M, Rigau M, Colás E, Garcia M, Montes M, Sequeiros T, Regis L, Celma A, Planas J, Placer J, Reventós J, de Torres I, Doll A, Morote J. Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines. Biomed Res Int. 2015;2015:762178. doi: 10.1155/2015/762178. Epub 2015 Jan 12. PMID: 25649906; PMCID: PMC4306438.
  19. Trilla E, Lorente D, Salvador C, Planas J, Placer J, Celma A, Cantarell C, Moreso F, Seron D, Morote J. Native ureteropyelostomy in the treatment of obstructive uropathy in adult renal transplant. Experience and technical alternatives. Actas Urol Esp. 2014 Oct;38(8):552-6. English, Spanish. doi: 10.1016/j.acuro.2014.02.004. Epub 2014 Mar 11. PMID: 24636074.
  20. Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventós J, Doll A. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci. 2014 Aug 6;15(8):13615-23. doi: 10.3390/ijms150813615. PMID: 25101846; PMCID: PMC4159814.
  21. Morote J, Ropero J, Planas J, Celma A, Placer J, Ferrer R, de Torres I. Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. Actas Urol Esp. 2014 Jun;38(5):285-9. English, Spanish. doi: 10.1016/j.acuro.2013.09.008. Epub 2013 Dec 20. PMID: 24360772.
  22. Bastarós J, Placer J, Celma A, Planas J, Morote J. Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. Actas Urol Esp. 2014 May;38(4):270-5. English, Spanish. doi: 10.1016/j.acuro.2013.10.001. Epub 2014 Feb 14. PMID: 24529539.
  23. Morote J, Celma A, Planas J, Placer J, Konstantinidis C, Iztueta I, de Torres IM, Oliván M, Reventós J, Doll A. Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes. Actas Urol Esp. 2014 May;38(4):232-7. English, Spanish. doi: 10.1016/j.acuro.2013.09.001. Epub 2013 Oct 21. PMID: 24156935.
  24. Celma A, Servián P, Planas J, Placer J, Quilez MT, Arbós MA, de Torres I, Morote J. Clinical significance of proliferative inflammatory atrophy in prostate biopsy. Actas Urol Esp. 2014 Mar;38(2):122-6. English, Spanish. doi: 10.1016/j.acuro.2013.04.008. Epub 2013 Oct 13. PMID: 24129226.
  25. Menéndez V, Fernández-Suárez A, Placer J, García-Linares M, Tarragon S, Liso E. Dhat syndrome, an emergent condition within urology in Spain. World J Urol. 2013 Aug;31(4):941-5. doi: 10.1007/s00345-012-0911-4. Epub 2012 Jul 27. PMID: 22836230.
  26. Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013 Jun;111(7):1031-6. doi: 10.1111/j.1464-410X.2012.11406.x. Epub 2012 Aug 9. PMID: 22883053.
  27. Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int. 2013;90(1):41-4. doi: 10.1159/000342814. Epub 2012 Dec 12. PMID: 23235105.
  28. Masferrer E, Ferrándiz-Pulido C, Lloveras B, Masferrer-Niubò M, Espinet B, Salido M, Rodríguez-Rivera M, Alemany L, Placer J, Gelabert A, Servitje O, García-Patos V, Pujol RM, Toll A. MYC copy number gains are associated with poor outcome in penile squamous cell carcinoma. J Urol. 2012 Nov;188(5):1965-71. doi: 10.1016/j.juro.2012.07.003. Epub 2012 Sep 20. PMID: 22999547.
  29. Salvador C, Planas J, Raventós C, Ropero J, Placer J, López MA, Morote J. Impacto de la supresión androgénica sobre el perfil lipídico y el riesgo aterogénico en pacientes con cáncer de próstata [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients]. Actas Urol Esp. 2012 Apr;36(4):205-9. Spanish. doi: 10.1016/j.acuro.2011.09.006. Epub 2011 Dec 16. PMID: 22178349.
  30. Galván AB, Salido M, Espinet B, Placer J, Pijuan L, Juanpere N, Lloreta J, Solé F, Gelabert-Mas A. A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscleinvasive urothelial cell carcinoma: A prospective study. Cancer Cytopathol. 2011 Dec 25;119(6):395-403. doi: 10.1002/cncy.20168. Epub 2011 Jun 29. PMID: 21717592.
  31. Placer J, Morote J. Utilidad del antígeno prostático específico (PSA) para el diagnóstico y estadificación de los pacientes con cáncer de próstata [Usefulness of prostatic specific antigen (PSA) for diagnosis and staging of patients with prostate cancer]. Arch Esp Urol. 2011 Oct;64(8):659-80. Spanish. PMID: 22052750.
  32. Placer J, López MA, Raventós C, Planas J, Salvador C, Ropero J, Morote J. Enucleación del adenoma prostático mediante el láser de Holmio (HOLEP) [Holmium laser enucleation of the prostatic adenoma]. Arch Esp Urol. 2011 Apr;64(3):246-56. Spanish. PMID: 21498890.
  33. Placer J. Comentario a: "Enucleación prostática con láser de diodo 980nm (Dilep): técnica y resultados iniciales" [Comment to: "Enucleation of the prostate with 980 mm diode laser (Dilep): technique and initial results"]. Actas Urol Esp. 2011 Jan;35(1):42-3. Spanish. doi: 10.1016/j.acuro.2010.11.002. PMID: 21322832.
  34. Placer J, Morote J. Re: Endo et al.: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence (Urology 2010;76:1451-1455). Urology. 2011 Jan;77(1):255-6; author reply 256-7. doi: 10.1016/j.urology.2010.09.054. PMID: 21195850.
  35. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventós CX, Placer J, de Torres IM, Reventós J, Doll A. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol. 2010 Dec;28(6):677-80. doi: 10.1007/s00345-010-0580-0. Epub 2010 Jul 7. PMID: 20607245.
  36. del Rey J, Placer J, Vallmanya F, Pujol N, Prat E, Miró R, Gelabert A. Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial? BJU Int. 2010 Jul;106(1):49-52. doi: 10.1111/j.1464-410X.2009.09081.x. Epub 2009 Nov 17. PMID: 19922541.
  37. Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010 Feb;105(4):481-4. doi: 10.1111/j.1464-410X.2009.08761.x. Epub 2009 Aug 13. PMID: 19681902.
  38. Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22. PMID: 19549260.
  39. Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, Arango O. Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve. Urology. 2009 May;73(5):1042-8. doi: 10.1016/j.urology.2008.12.052. PMID: 19394500.
  40. Vallmanya F, Placer J, Pou Serradell A, Cortadellas R, Gelabert-Mas A. Tuberous sclerosis complex. Forty-years of follow-up of a patient affected. Arch Esp Urol. 2006 Jan-Feb;59(1):105-7. doi: 10.4321/s0004-06142006000100020. PMID: 16568704.
  41. Salido M, Lloreta J, Melero C, García M, Placer J, Espinet B, Villa O, Bielsa O, Gelabert-Mas A, Serrano S, Solé F. Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma. Cancer Genet Cytogenet. 2005 Dec;163(2):160-3. doi: 10.1016/j.cancergencyto.2005.04.016. PMID: 16337860.
  42. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: a FISH study. Urology. 2005 May;65(5):913-8. doi: 10.1016/j.urology.2004.11.013. PMID: 15882723.
  43. Placer J, Cortadellas R, Grases F, Gelabert-Mas A. Fecal and urinary obstruction by a stone in ureterosigmoidostomy. J Urol. 2003 Aug;170(2 Pt 1):516. doi: 10.1097/01.ju.0000075142.14770.78. PMID: 12853812.
  44. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol. 2002 Dec;42(6):547-52. doi: 10.1016/s0302-2838(02)00448-7. PMID: 12477649.